Ethema Health Corp (GRST)

[Bubae]

Look, here is the run down below. around 370 million shares traded so far this month of which only 39 million is dilution. It is just my opinion and I'm sure many others that the price dopping as much as 27% this month with so little selling pressure from dilution isn't good.

Especially since LABRYS fund is sitting on a ton of eligible conversions right now. The company needs to get another biannual refi done for two reasons in my opinion. One that $230K for operating they got the first of June has to be running thin. Second they need to pull back some of the debt conversion pressure because LABRYS isn't the only one holding debt here. A third reason is they need some trading volume that their "paid off debt" refi press releases bring despite false notion of actually reducing debt. Those two LABRYS fund financing notes of $780K convert into shares at twice the face value because of the price protections. That is a lot of conversions... for only the two notes.

https://sec.report/Document/0001721868-21-000524/

Authorized and outstanding
The Company has authorized 10,000,000,000 shares with a par value of $0.01 per share. The company has issued and outstanding 2,601,515,456 and 2,027,085,665 shares of common stock at June 30, 2021 and December 31, 2020, respectively.

Outstanding Shares----2,601,515,456----06/30/2021
Outstanding Shares----2,813,515,456----07/12/2021
Outstanding Shares----2,899,848,789----08/24/2021
Outstanding Shares----2,959,108,419----09/24/2021
Outstanding Shares----3,051,047,811----09/27/2021
Outstanding Shares----3,111,047,811----09/29/2021
Outstanding Shares----3,173,047,811----10/13/2021
Outstanding Shares----3,181,270,033----10/18/2021
Outstanding Shares----3,231,766,761----10/26/2021
Outstanding Shares----3,315,538,708----11/01/2021
Outstanding Shares----3,354,944,018----11/16/2021


7 payments appear to still be left on the LABRYS note maturing on November 30th. 3 payments were made and noted in the May 7th LABRYS financing deal.

https://sec.report/Document/0001721868-21-000288/#f2sgrst8k051321ex10_01.htm

"On April 30, 2021 the Company was given notice of three payments of 30,800 due on April 30, 2021 under the note entered into on November 24, 2020 in the aggregate principal amount of $275,000 were going to be converted into common shares of the Company and 100,000,000 restricted shares were issued. The Company still has seven more payments of 30,800 due under the note."

https://sec.report/Document/0001721868-21-000524/
On November 30, 2020, the Company, entered into a Securities Purchase Agreement with Labrys, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $275,000 for net proceeds of $239,050 after an original issue discount of $27,500 and certain legal expenses. The Note has a maturity date of November 30, 2021 and bears interest at the rate of twelve percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Labrys during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to 60% of the lowest closing bid price of the Company’s common stock for the thirty trading days prior to conversion.


https://sec.report/Document/0001721868-21-000524/

"All of the warrants outstanding at June 30, 2021 are vested. The warrants outstanding at June 30, 2021 have an intrinsic value of $2,219,035."

Twitter
https://twitter.com/HealthEthema

Quote:
Ethema Health
@HealthEthema
·
Sep 30
Last few days Labrys Fund exercised 2 warrants for restricted shares of 92M which are restricted until Nov and Dec and 60M unrestricted for conversion of debt. $GRST

https://sec.report/Document/0001721868-21-000524/

"On May 7, 2021, the Company, entered into a Securities Purchase Agreement with Labrys, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $550,000 for net proceeds of $477,700 after an original issue discount of $55,000 and certain legal expenses of $17,300. The Note has a maturity date of May 7, 2022 and bears interest at the rate of eleven percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Labrys during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to $0.005, subject to anti-dilution adjustments."

"On June 2, 2021, the Company, entered into a Securities Purchase Agreement with Labrys, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $230,000 for net proceeds of $200,000 after an original issue discount of $23,000 and certain legal expenses of $7,000. The Note has a maturity date of June 2, 2022 and bears interest at the rate of eleven percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Labrys during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to $0.004, subject to anti-dilution adjustments."


https://sec.report/Document/0001721868-21-000350/

anti-dilution adjustment based on par value for conversion is .01

1.1 Conversion Right. The holder on any calendar day, at any time on or following the issue date, to convert all or any portion of the then outstanding and unpaid Principle Amount and interest (including any Default Interest) into fully paid and non-assessable shares of Common Stock.

1.2 Conversion Price

(a) Calculation of Conversion Price The per share conversion price into which Principle Amount and interest (including any Default Interest) under this Note shall be convertible into Common Stock hereunder (the “Conversion Price”) shall equal $0.005. If at any time the Conversion Price as determined hereunder for any conversion would be less than par value of the common stock, then at the sole discretion of the Holder, the conversion price hereunder may equal such par value for such conversion and the Conversion Amount for such conversion may be increased to include Additional Principle, where “Additional Principle” means such additional amount to be added to the conversion amount to the extent necessary to cause the number of conversion shares issuable upon such conversion to equal the same number of conversion shares as would have been issued had the Conversion Price not been adjusted by the Holder to the par value price.

LABRYS Fund $550K financing, May 2021
https://sec.report/Document/0001721868-21-000288/#f2sgrst8k051321ex10_02.htm

LABRYS Fund $230K financing, June 2021
https://sec.report/Document/0001721868-21-000350/#f2sgrst8k060921ex10_02.htm